Yamada A, Horimatsu T, Okugawa Y, Nishida N, Honjo H, Ida H, Kou T, Kusaka T, Sasaki Y, Makato Y, Higurashi T, Yukawa N, Amanuma Y, Kikuchi O, Muto M, Ueno Y, Nakajima A, Chiba T, Boland CR, Goel A.

Serum miR-21, miR-29a and miR-125b are promising biomarkers for the early detection of colorectal neoplasia.

Clin Cancer Res. 2015 Sep 15;21(18):4234-42.

Sato F, Kubota Y, Natsuizaka M, Maehara O, Hatanaka Y, Marukawa K, Terashita K, Suda G, Ohnishi S, Shimizu Y, Komatsu Y, Ohashi S, Kagawa S, Kimugasa H, Whelan KA, Nakagawa H, Sakamoto N.

EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.

Cancer Biol Ther. 2015, 16(6) : 933-40

Fujiwara Y, Kobayashi S, Nagano H, Kanai M, Hatano E, Toyoda M, Ajiki T, Takashima Y, Yoshimura K, Hamada A, Minami H, Ioka T.

Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101).

PLoS One. 2015 Dec 3;10(12):e0143072.

Kishi T, Nakamura A, Itasaka S, Shibuya K, Matsumoto S, Kanai M, Kodama Y, Takaori K, Mizowaki T, Hiraoka M.

Pretreatment C-reactive protein level predicts outcome and patterns of failure after chemoradiotherapy for locally advanced pancreatic cancer.

Pancreatology. 2015 Nov-Dec;15(6):694-700

Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I.

Safety and anti-tumor activity of anti-PD-1 antibody (nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer.

J Clin Oncol. 2015 Dec 1;33(34):4015-22.

Hatano E, Kanai M, Nagano H, Ioka T.

Clinical study of new chemotherapy regimen for biliary tract cancer.

Nihon Rinsho. 2015 Mar;73 Suppl 3:805-8.

Kitayama H, Tsuji Y, Sugiyama J, Doi A, Kondo T, Hirayama M.

Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study.

Int J Clin Oncol. 20:1051- 1056, 2015.

Kanai M, Hatano E, Kobayashi S, Fujiwara Y, Marubashi S, Miyamoto A, Shiomi H, Kubo S, Ikuta S, Yanagimoto H, Terajima H, Ikoma H, Sakai D, Kodama Y, Seo S, Morita S, Ajiki T, Nagano H, Ioka T.

A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).

Cancer Chemother Pharmacol. 2015 Feb; 75(2):293-300.

Nomura M, Oze I, Abe T, Komori A, Narita Y, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Andoh M, Kawai R, Uemura N, Ishihara M, Tanaka T, Tajika M, Niwa Y, Muro K, Muto M.

Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis.

Cancer Chemother Pharmacol 2015 Aug;76(2):357-63.

Osamu kikuchi, Shinya Ohashi, Yukie Nakai, Shunsaku Nakagawa, Kazuaki Matsuoka, Takashi Kobunai, Teiji Takechi, Yusuke Amanuma, Masahiro Yoshioka, Tomomi Ida, Yoshihiro Yamamoto, Yasushi Okuno,Shin’ichi Miyamoto, Hiroshi Nakagawa, Kazuo Matsubara, Tsutomu Chiba, and Manabu Muto.

Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression.

American Journal of Cancer Research 2015 Jul 15;5(8):2431-40. eCollection 2015.